key: cord-0797483-xf41yblb
authors: Uddin, Reaz; Jalal, Khurshid; Khan, Kanwal; ul-Haq, Zaheer
title: Re-Purposing of Hepatitis C Virus FDA Approved Direct Acting Antivirals as Potential SARS-CoV-2 Protease Inhibitors
date: 2021-11-19
journal: J Mol Struct
DOI: 10.1016/j.molstruc.2021.131920
sha: 99574da5df8ac95005a9ead099a0daf6769f85ad
doc_id: 797483
cord_uid: xf41yblb

A new coronavirus strain called as SARS-CoV-2 has emerged from Wuhan, China in late 2019 and it caused a worldwide pandemic in a few months. After the Second World War, it is the biggest calamity observed as there is no specific US Food and Drugs Administration (USFDA) approved drug or vaccine available globally for the treatment. Several clinical trials are ongoing for therapeutic alternatives, however with little success rate. Considering that the time is crucial, the drug repurposing and data obtained from in silico models are one of the most important approaches to identify possible lead inhibitors against SARS-CoV-2. More recently, the Direct Acting Antivirals (DAAs) are emerged as the most promising drugs to control viral infection. The Main Protease (Mpro), a key enzyme in the SARS-CoV-2 replication cycle, is found close homolog to the Hepatitis C Virus (HCV) protease and could be susceptible of blocking its activity by DAAs. In the current study, the DAAs were investigated as antivirals using structure based computational approach against Mpro of SARS-CoV-2 to propose them as new therapeutics. In total, 20 DAAs of HCV, including a reference compound O6K were docked against Mpro. The docked structures were examined and resulted in the identification of six highly promising DAAs i.e. beclabuvir, elbasvir, paritaprevir, grazoprevir, simeprevir, and asunapevir exhibiting high theoretical binding affinity to Mpro from SARS-CoV-2 in comparison to other DAAs. Furthermore, the post docking analysis revealed that Cys145, Glu166, His163, Thr26, His41, and Met165 played potential role for the binding of these DAAs inside binding site of Mpro. Furthermore, the correlation between binding energies were found in accord with the results from the reported IC(50)s for some DAAs. Overall, the current study provides insight to combat COVID-19 using FDA-approved DAAs as repurposed drugs.

An acute respiratory disease that is causing progressive lung injury was reported to World Health Organization (WHO) in the late 2019. The disease was first detected from Wuhan (China) and subsequently announced as new coronavirus disease. It was labelled as in February 2020 (Pawlotsky, 2020) . The COVID-19 is responsible for more than 10 million infected cases, and more than 450,000 deaths just in few months from 196 countries (the number is still progressing). Therefore, the World Health Organization (WHO) declared SARS-CoV-2 as the new coronavirus as a global pandemic on March 11, 2020 (Wu et al., 2020) . The world has been battling with this highly infectious COVID-19 disease for more than two years i.e. ~131,965,495 positive cases and 2,867,083 deaths (as of April 05, 2021) worldwide. Furthermore, recent studies indicated that COVID-19 not only affects the lung tissues but also exhibits adverse effects on the other organs such as heart, brain and kidneys, thus indicating that potent anti-COVID-19 agent should possess a tendency toward these target organs. Current prevention is based on quarantine to prevent its transmission. However, many promising treatments are yet to complete their clinical trials (Al-Karmalawy et al., 2021) . Although WHO approved vaccines (i.e.

Sinopharm, Sinovac, Pfizer, AstraZeneca and many others) are being used for the time being, still certain side effects (such as blood clotting etc) are reported related to specific vaccine. Therefore, more therapeutics are urgently required for this fast-moving pandemic so that the world is prepared for next wave. An extensive effort is being performed from researchers around the world to combat this virus.

The SARS-CoV-2 is a positive-sense single-stranded RNA virus belongs to the same family as SARS-CoV, i.e. coronaviridae. It has a largest genome among other known RNA viruses (Wu et al., 2020) . Its replication mechanism requires a number of key enzymes, notably helicases, main protease (Mpro) and RNA-dependent RNA-polymerase (RdRp). It is consisting of six Open Reading Frames (ORFs) . The first ORF (ORF1a/b) is composed of two-third of RNA genome and encodes for two polypeptides i.e. pp1a and pp1ab while the remaining five ORFs make up of one-third of RNA genome responsible for the production of membrane protein (M), envelope protein (E), nucleocapsid protein (N) and spike protein (S) (Jin et al., 2020) . Likewise, Hepatitis C virus is also a positive-sense single-stranded RNA virus belongs to the Flaviviridae family. It is classified into eight different major genotypes. The NS3 mediates the production of protease, NS4A/B mediates four polyproteins cleavage events while NS5A/B encodes for the polymerases for viral cycle. It is observed that HCV proteins share the similar genomic construction as SARS-CoV-2 ( Figure 1 ) (Bafna et al., 2020) .

However, the two polypeptides generated from first ORFs (pp1a and pp1ab) encodes for a number of vital Nonstructural Proteins (NSPs), among which is NSP5 (a cysteine 3C-like protease) known as main protease (Mpro). The Mpro protein mediates the production of important NSPs crucial for the viral infection cycle i.e. RNA-dependent RNA polymerase, methyltransferase, and helicase (Song et al., 2018) . Hence, the main protease controls the major pathways and replication of viral genome, it can be used as attractive drug target to halt the replication event in the virus life cycle (Mody et al., 2021) . It is three-domain (domains I to III) cysteine protease having active site between domains I and II. The main protease (NS3) of HCV is a chymotrypsin-like serine protease (Anand et al., 2002) .

Recently developed highly effective therapeutics of HCV are the inhibitors of this protease.

The combination of antivirals especially DAAs that directly targets the HCV proteins share the similar genomic construction as SARS-CoV-2 ( Figure 2 ). These similarities have led to the investigation of existing HCV Direct Acting Antiviral (DAA) against COVID-19 as potential therapies (Chan, 2020) . The DAAs are effective antivirals used against HCV protease and HCV polymerase and RNA-dependent RNA polymerase (Izzi et al., 2020) .

European Medicine Agency (Mengist et al.) for the HCV as pan-genotypic treatment (Pelly & Liotta, 2021) . Recently, the concept of drug re-purposing has been widely used because of the drugs approved for one disease have considerable advantage in terms of time and cost, pharmacokinetics and toxicity being investigated in humans (Bafna et al., 2021) . The drug re-purposing is one of the promising approaches in recent days to bring about innovative cures by the existing FDA approved drugs (Hamed et al., 2021) . Therefore, the current study was aimed to identify the candidate drugs using a computational approach of molecular docking. For this purpose, a library of FDA-approved Hepatitis C DAAs drugs was investigated to find their potential for re-purposing as anti-SARS-CoV-2 drugs against Mpro.

In the current study, an in-silico based molecular docking approach was applied for the DAAs of HCV for the prioritization of novel drug candidates against SARS-CoV2. The complete work flow of the current study is presented in Figure 3 .

The COVID-19 main protease (PDB ID: 6Y2G) was obtained from the Protein Data Bank (Rose et al., 2021) in PDB format. The protein contained two chains (A, and B), having a sequence length of 306 amino acids. The 6Y2G protein was incorporated with ligand i.e. ID 06K, IUPAC Name: ~{tert}-butyl ~{N}-[1-[(2~{S})-3-cyclopropyl-1-oxidanylidene-1-

The 20 FDA reported DAAs (beclabuvir, boceprevir, dasabuvir, glecaprevir, paritaprevir, pibrentasvir, ribavirin, ritonavir, telaprevir, velpatasvir, asunaprevir, voxilaprevir, daclatasvir, elbasvir, faldaprevir, omitasvir, grazoprevir, simeprevir, sofosbuvir, and ledipesvir) were Table 1 showed the dataset of selected DAAs.

The obtained protein crystal structure was prepared and further refined for molecular docking study. The water molecules were removed while polar hydrogens were added to PDB structure. Kollam united atom force field was used to add charges to protein structure by AutoDock 4.2 (Huey et al., 2012; Morris et al., 2009) . Then the structure was saved in a PDBQT format for further molecular docking calculations.

The DAAs library used as ligands for this study was processed and prepared for docking studies. The retrieved PDB structures were energy minimized through Frog2 tool (Miteva et al., 2010) . The minimized 20 DAAs were further analyzed via AutoDock and the gasteiger charges were computed. The saved PDBQT files were used for docking analysis.

The grid box for Mpro was generated through AutoDock tool (Huey et al., 2012; Morris et al., 2009) , around the active site defined by already co-crystalized ligand present in PDB structure with the binding pocket. The grid box dimensions were generated as point 46, 48, and 50 for X, Y, and Z dimensions while the Grid Box center was set as -19.942, -6.232, and -26.819 for X, Y, and Z center, respectively.

Molecular docking is commonly used structure-based approach to highlight the binding mode of compounds with selected proteins in terms of Van der Waals, binding affinities, 

The re-docking is performed to assess the performance of any docking program so that it is decided if the docking program is capable of reproducing the same crystal conformation of the bound ligand or not? The re-docking experiment in the case of Mpro was employed by the AutoDock with its co-crystalized ligand.

The MOE tool was used to investigate the docked DAAs and Mpro complex interaction to visualize the hydrogen and hydrophobic interaction of complex within the range of 5Å.

Moreover, the correlation between IC 50 and binding affinity was also studied for DAAs and Mpro protein. The IC 50 s were retrieved from literature mining while the docked binding energies were predicted through AutoDock tool (Gammeltoft et al., 2020) .

The molecular docking study was carried out to analyze the binding mode of the DAAs against Mpro protein of SARS-CoV-2. The docking analysis highlights the interaction of compounds with crucial amino acids residues present at the active site with binding energies obtained from docking results are given in Table 2 . The molecular docking results demonstrated in terms of negative energy and indicating that the lower the binding energy scores, best would be the binding affinity of the ligand to its receptor (Labib et al., 2018) .

The docking study revealed that, Ombitasvir mediates two hydrogen bond interaction with Figure S8) .

It was observed through docking analysis that Velpatasvir formed interactions with an estimated binding energy of -9.4 Kcal/mol. It mediates multiple hydrogen bonds as backbone hydrogen donor to Gly143, Thr26 and Glu166. Additionally, it has made an arene -H interaction between the heterocyclic aromatic ring of Velpatasvir and the Thr26.

(Supplementary Figure S9) .

The docking study of Voxilaprevir revealed that it mediates two hydrogen bonds with Mpro protein. It was found that Gln189 and His41 act as hydrogen bond partners with the Voxilaprevir atoms. The docking score calculated for voxilaprevir was -8.77 Kcal/mol (Supplementary Figure S10) .

Asunaprevir mediates ten hydrogen bonds with an estimated binding energy of -9.99

Kcal/mol. The docking study highlights that Glu166 formed two hydrogen bonds between quinolone ring as a hydrogen donor (side chain hydrogen donor). The same Glu166 mediates one hydrogen bond with side chain oxygen of pyrrole ring as backbone hydrogen donor with a distance of 2.95 Å. While His41, Cys145, and Asn142 interact with oxygens of sulfonamide group, nitrogen found at side chain and chlorine of quinolone ring through hydrogen bonds having a bond distance of 3.16 and 3.05 Å, respectively. Furthermore, Ser144 and Gly143 mediate three hydrogen bonds as backbone hydrogen donor to oxygen of sulfonamide group with the bond distance of 3.04, 2.81, and 2.95 Å, respectively (Supplementary Figure S11) .

The docked structure of Daclatasvir showed estimated binding energy as -6.75 Kcal/mol.

The study showed it mediates one hydrogen bond with Mpro protein through Leu27 interacting with imidazole ring (Supplementary Figure S12) .

Elbasvir drug facilitates significant interaction with Mpro protein resulting in the second highest estimated binding energy of -11.92 Kcal/mol. It mediates multiple hydrogen bonds with different active site residues. Thr26 acts as backbone hydrogen acceptor, mediating one hydrogen bond with nitrogen. Glu166 was found to mediate three hydrogen bonds with imidazole ring as side chain and backbone hydrogen acceptor to Elbasvir ( Figure 5C ).

The docked structure of Faldaprevir showed estimated binding energy of -7.60 Kcal/mol. It mediated two hydrogen bonds as side chain and backbone acceptor with Cys145.

Gln189 formed one hydrogen bond as side chain hydrogen acceptor to carboxylic oxygen adjacent to cyclopropane ring (Supplementary Figure S13) .

Grazoprevir exhibited one of the most significant binding energy estimated as -11.37

Kcal/mol. The docking study revealed that Grazoprevir mediate multiple hydrogen bonds as hydrogen acceptor and donor (from backbone) with Gly143, His164 and Cys145 residues to the oxygen of sulfonamide group ( Figure 5D ). It has mediated total of seven hydrogen bonds with active amino acids. Ser144 formed one hydrogen bond with oxygen of side chain, Cys145 formed two hydrogen bonds with oxygen as hydrogen acceptor and donor, Met165 formed one hydrogen bond with nitrogen of pyrrole ring, while His164 formed one hydrogen bond with oxygen of pyrrole ring and the other with hydroxyl group ( Figure 5E ).

The docking study revealed that compounds Beclabuvir, Paritaprevir, Asunaprevir, Elbasvir, Grazoprevir, and Simeprevir have shown high binding energies i.e. from -9.9 to -11 Kcal/mol (i.e. greater than test compound). The complete binding interactions of DAAs with Mpro proteins are presented in Table 4 .

In the current study, the correlation between IC 50 (identified through literature mining) and calculated binding energies was also investigated. The IC 50 s for eight compounds out of twenty DAAs against Mpro enzyme were found in whole cell culture. The Table 3 reported the IC 50 of each compound and the corresponding source reference. The correlation predicted for these eight compounds along with their binding energies was estimated to be 0.725 ( Figure 6 ). This high correlation classified this study as significant. The correlation identification helped to find a relation that lower the binding energy (i.e. higher negative value), lower will be the IC 50 value. The significant relationship between the IC 50 and binding energies provides an insight for further prediction of IC 50 of unknown compounds.

The current pandemic coronavirus disease 2019 (SARS-CoV-2, previously known as 2019-nCoV) is classified as serious global threat to humans resulting in 54 million confirmed cases, growing at rates of up to 600,000 new cases/day while over 181,000 deaths (Gurung, 2020)(as of 24 April 2020) with an estimated fatality rate of 3% (Worldometer 2020, https://www.worldometers.info/coronavirus/). This pandemic emerged as deadly disease that is damaging the alveoli, resulting in respiratory failure and subsequent death. Due to barely accessible affected patient's report of biopsy and autopsy, the pathology of COVID disease is unclear. Despite numerous approaches (such as personal protection, social distancing, and disinfection), all treatments measure that employed anti-inflammatory and antivirals are supportive to only treat the symptoms of COVID disease, while no specific antiviral drugs have been confirmed to be effective yet (Chan, 2020) . The greatest challenge today is to effectively control the spread of the pandemic until a successful vaccine is available (Mengist et al., 2021) .

The Direct Acting Antivirals (DAAs) are newly emerged class of antivirals used for the treatment of HCV (Matthew et al., 2021) . The DAAs inhibit the NS3/4A protease, the NS5A protein, and the NS5B polymerase proteins of HCV providing an effective treatment approach. The DAAs have revolutionized the HCV treatment based on their favorable side effects profiles and enhanced rates of sustained virological response. The Mpro (Main Protease) is classified as one of the key enzymes responsible for the replication and transcription of coronavirus. Accordingly, Mpro could be an interesting target to explore the efficacy of any drug against coronavirus. Due to the similarities found in HCV and SARS-CoV2 genomics and proteomics, the drug repurposing of DAAs against Mpro of COVID was applied in the current study (Bafna et al., 2021) .

This study was aimed to consider DAAs (due to the striking activity against the HCV protease) against Mpro from SARS-CoV-2 and proposed them to be evaluated against COVID-19. The repurposed drugs can skip the prior screening and could move directly to the clinical trials and approved by the FDA for an immediate indication (Chakraborti et al., 2020) . The DAAs of HCV such as Beclabuvir, Boceprevir, Dasabuvir, Glecaprevir, Paritaprevir, Pibrentasvir, Ribavirin, Ritonavir, Telaprevir, Velpatasvir, Asunaprevir, Voxilaprevir, Daclatasvir, Elbasvir, Faldaprevir, Omitasvir, Grazoprevir, Simeprevir, Sofosbuvir, and Ledipasvir were tested in silico for their potential as a treatment for COVID-19. Earlier, successful repurposed drugs have been approved such as use of Aspirin for the treatment of coronary artery diseases and the use of Sildenafil to treat erectile dysfunction (Rudrapal et al., 2020) .

Herein, the docking study of selected twenty DAAs was conducted against Mpro through AutoDock along with the crystallized ligand as reference compound to identify novel compounds against Mpro and validate the current study. The docking study revealed that all compounds were computationally predicted with the lowest binding energies ranging from ~-4 to -11 Kcal/mol, and formed stable interactions through intermolecular hydrogen bonds. It was found that six compounds i.e. Beclabuvir, Paritaprevir, Asunaprevir, Elbasvir, Grazoprevir, and Simeprevir showed standard minimum binding energies of -9.9 to -11.9

kcal/mol compared with the reference compound (i.e. -9.7 Kcal/mol) and they exhibited tight interactions against Mpro with stable docking and higher binding energies.

Paritaprevir, Asunaprevir, Grazoprevir, and Simeprevir are protease inhibitors (for HCV),

Beclabuvir is a non-nucleoside polymerase inhibitor of the hepatitis C virus (HCV) nonstructural protein 5B (NS5B), while Elbasvir is hepatitis C virus nonstructural protein 5A

inhibitor (Wishart et al., 2018) .

To get insight in to the intermolecular interactions, the molecular docking studies were further analyzed through MOE tool. The post docking analysis of these compounds showed that most of the hydrogen bonds formed between DAAs and Mpro mediates the involvement of GLU166, CYS145, MET165, ASN142, HIS41, THR26, and HIS164 active site residues reported as most significant amino acids present at the active site of Mpro enzyme. In addition, our findings may help in understanding the structure and activity relationship requirements for Mpro targeting drugs. For example, the essential role of the pyrimidine moiety and imidazole moiety in the six prioritized compounds were found as mediating the most significant hydrogen bonds with the crucial amino acids of the active site through its azole and pyrrolidine rings. This finding may help to innovate the new drug candidates against COVID-19. Furthermore, the docked binding energies and IC 50 through literature survey were examined to find the correlation among them. It was observed through correlation analysis that the higher negative binding energy value resulted in lower IC 50 value.

Finally, this study found a correlation among the affinities of the tested anti-HCV drugs against COVID-19 protease. Accordingly, we suggest such drugs for the repurposing pathway to reach an effective therapy for pandemic COVID-19. Furthermore, these drugs could be used either alone or in combination with each other's or with interferons as in the case with the Hepatitis C virus.

The emergence of COVID-19 variants is a major bottle-neck in the discovery of a successful molecular therapeutic. Therefore, understanding of the molecular basis of the available FDA approved drugs is a key to find new treatment options. The successful application of DAAs against HCV grabs the attention to try them against COVID-19 also.

Hence, twenty DAAs of HCV were subjected to molecular docking against SARS-CoV-2 main protease. The docking analysis revealed the variable affinities of these DAAs towards SARS-CoV-2 Mpro compared to the O6K reference compound. However, the six shortlisted DAAs are recommended for further clinical testing against COVID-19.

Nevertheless, before clinical recommendations of these six shortlisted DAAs against COVID-19, it is highly recommended to conduct larger, dose determining, randomized, and prospective controlled clinical trial. 

Molecular docking and dynamics simulations reveal the potential of anti-HCV drugs to inhibit COVID-19 main protease

Structure of coronavirus main proteinase reveals combination of a chymotrypsin fold with an extra α-helical domain

Structural similarity of SARS-CoV2 Mpro and HCV NS3/4A proteases suggests new approaches for identifying existing drugs useful as COVID-19 therapeutics

Hepatitis C virus drugs that inhibit SARS-CoV-2 papain-like protease synergize with remdesivir to suppress viral replication in cell culture

Repurposing drugs against the main protease of SARS-CoV-2: mechanism-based insights supported by available laboratory and clinical data

Current and future direct-acting antivirals against COVID-19

Hepatitis C virus protease inhibitors show differential efficacy and interactions with remdesivir for treatment of SARS-CoV-2 in Vitro

In silico structure modelling of SARS-CoV-2 Nsp13 helicase and Nsp14 and repurposing of FDA approved antiviral drugs as dual inhibitors

Direct acting anti-hepatitis C combinations as potential COVID-19 protease inhibitors

Using AutoDock 4 and AutoDock vina with AutoDockTools: a tutorial. The Scripps Research Institute Molecular Graphics Laboratory

Editorial-Sofosbuvir/Velpatasvir as a combination with strong potential activity against SARS-CoV2 (COVID-19) infection: how to use direct-acting antivirals as broad-spectrum antiviral agents

Structure of Mpro from covid-19 virus and discovery of its inhibitors

Azole-hydrazone derivatives: Design, synthesis, in vitro biological evaluation, dual EGFR/HER2 inhibitory activity, cell cycle analysis and molecular docking study as anticancer agents

Analysis of the efficacy of HIV protease inhibitors against SARS-CoV-2′ s main protease

Drug design strategies to avoid resistance in direct-acting antivirals and beyond

Potency, safety, and pharmacokinetic profiles of potential inhibitors targeting SARS-CoV-2 main protease

Frog2: Efficient 3D conformation ensemble generator for small compounds

Identification of 3-chymotrypsin like protease (3CLPro) inhibitors as potential anti-SARS-CoV-2 agents

AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility

COVID-19 pandemic: time to revive the cyclophilin inhibitor alisporivir

Potent SARS-CoV-2 direct-acting antivirals provide an important complement to COVID-19 vaccines

RCSB Protein Data Bank: Architectural advances towards integrated searching and efficient access to macromolecular structure data from the PDB archive

Drug repurposing (DR): an emerging approach in drug discovery

Cryo-EM structure of the SARS coronavirus spike glycoprotein in complex with its host cell receptor ACE2

DrugBank 5.0: a major update to the DrugBank database

A new coronavirus associated with human respiratory disease in China

Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors

The authors would like to acknowledge the International Foundation for Science (IFS) for providing the research grant # I-1-F-5378-2.

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.